2020 in a nutshell: The hottest developments in the field of cardiology this year. Section 1. General and preventive cardiology - Page 4

Written By : dr. Abhimanyu Uppal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2020-12-24T12:45:33+05:30 | Updated On 26 Dec 2020 2:40 PM IST

4. EVAPORATE (Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy) trial

Icosapent ethyl 4 g/day reduces low attenuation plaque volume at 18 months compared with placebo among patients with known CAD, as assessed by cardiac CT angiography (CTA)

Eligible patients were randomized in a 1:1 fashion to either icosapent ethyl 4 g/day (n = 40) or placebo.

The results of this trial indicate that icosapent ethyl 4 g/day reduces low attenuation plaque volume compared with placebo at 18 months, as measured by cardiac CTA. In addition, there was a reduction in total plaque volume and other plaque parameters as well. In the setting of a small sample size, there was no difference in triglyceride levels. These results may help explain the cardiovascular benefit noted with icosapent ethyl in the REDUCE-IT trial. Source: European Heart Journal: Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J 2020;Aug 29

cardiology updatescardiology trials 2020latest cardiology developments

dr. Abhimanyu Uppal

MBBS, MD , DM Cardiology

Dr Abhimanyu Uppal completed his M. B. B. S and M. D. in internal medicine from the SMS Medical College in Jaipur. He got selected for D. M. Cardiology course in the prestigious G. B. Pant Institute, New Delhi in 2017. After completing his D. M. Degree he continues to work as Post DM senior resident in G. B. pant hospital. He is actively involved in various research activities of the department and has assisted and performed a multitude of cardiac procedures under the guidance of esteemed faculty of this Institute. He can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751